Cargando…

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies

BACKGROUND: While response rates to anti-PD1 therapy are low in unselected metastatic castration resistant prostate cancer (mCRPC) patients, those with inactivating mutations in mismatch repair (MMR) genes (i.e. MMR deficiency; MMRd) or microsatellite instability (MSI) are thought likely to respond...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graham, Laura S., Montgomery, Bruce, Cheng, Heather H., Yu, Evan Y., Nelson, Peter S., Pritchard, Colin, Erickson, Stephanie, Alva, Ajjai, Schweizer, Michael T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250457/ https://www.ncbi.nlm.nih.gov/pubmed/32453797 http://dx.doi.org/10.1371/journal.pone.0233260

Ejemplares similares

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
por: Schweizer, Michael T., et al.
Publicado: (2016)

PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer
por: Liu, Ding-Xin, et al.
Publicado: (2020)

Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair–deficient, locally advanced rectal cancer
por: Mi, Mi, et al.
Publicado: (2022)

The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers
por: Wang, Qiao-Xuan, et al.
Publicado: (2021)

Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer
por: Sui, Qiaoqi, et al.
Publicado: (2021)

Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford
por: Abrha, Aser, et al.
Publicado: (2020)

Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022)

Correction: Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer
Publicado: (2021)

Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system
por: Hirsch, Daniela, et al.
Publicado: (2020)

Mismatch repair–deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade
por: Sena, Laura A., et al.
Publicado: (2021)

CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors
por: Salewski, Inken, et al.
Publicado: (2022)

Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer
por: Carlson, Alexander S., et al.
Publicado: (2020)

Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2022)

Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report
por: Reed-Perino, Darien E, et al.
Publicado: (2023)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
por: Nghiem, Belinda, et al.
Publicado: (2016)

Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference
por: Jensen, Kendal, et al.
Publicado: (2020)

PD-1 blockade restores impaired function of ex vivo expanded CD8(+) T cells and enhances apoptosis in mismatch repair deficient EpCAM(+)PD-L1(+) cancer cells
por: Kumar, Rajeev, et al.
Publicado: (2017)

Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair–Deficient Endometrial Cancer
por: Gulhan, Doga C., et al.
Publicado: (2020)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
por: Punturi, Nindo B., et al.
Publicado: (2021)

Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer
por: Jin, Zhaohui, et al.
Publicado: (2021)

Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer
por: Song, Yurong, et al.
Publicado: (2023)

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer
por: De Sarkar, Navonil, et al.
Publicado: (2021)

Clinical Characterization of Mismatch Repair Gene-Deficient Metastatic Castration-Resistant Prostate Cancer
por: Ye, Senlin, et al.
Publicado: (2020)

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
por: Wensink, G. Emerens, et al.
Publicado: (2020)

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
por: Zhao, Pengfei, et al.
Publicado: (2019)

Mismatch repair deficiency in ovarian cancer
por: Fuh, Katherine
Publicado: (2022)

Clinicopathologic features of endometrial cancer with mismatch repair deficiency
por: Gordhandas, Sushmita, et al.
Publicado: (2020)

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
por: Cohen, Romain, et al.
Publicado: (2021)

Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort
por: Zwart, Koen, et al.
Publicado: (2023)

Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody
por: Zhou, Wenyue, et al.
Publicado: (2021)

Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study
por: Cheng, Yi-Kan, et al.
Publicado: (2022)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
por: Saberzadeh-Ardestani, Bahar, et al.
Publicado: (2023)

Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma
por: Zhao, Liang, et al.
Publicado: (2019)

PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers
por: Siraj, Abdul K., et al.
Publicado: (2021)

Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma
por: Xia, Liming, et al.
Publicado: (2018)

Intraindividual Tumor Heterogeneity of Mismatch Repair Status in Metastatic Colorectal Cancer
por: Huang, Qianpeng, et al.
Publicado: (2023)

Biallelic Mismatch Repair Deficiency in an Adolescent Female
por: Hildreth, Amber, et al.
Publicado: (2018)

Assessment of mismatch repair deficiency in ovarian cancer
por: Crosbie, Emma J, et al.
Publicado: (2021)

Genetic Characteristics of Mismatch Repair-deficient Glioblastoma
por: KAWAGUCHI, Kei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5960btk5q565h2uf9mnsfmsbpo